Comparison of Voglibose and Acarbose on incretin secretion and postprandial metabolic parameters in type 2 diabetes

Comparison of Voglibose and Acarbose on incretin secretion and postprandial metabolic parameters in type 2 diabetes - Comparison of Voglibose and Acarbose on incretin secretion and postprandial metabolism

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003142

Enrollment

Registered

2010-04-01

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes patients

Interventions

Voglibose 0.3mg Acarbose 100mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Age 18 to 80 years 2)Diabetes mellitus (HbA1c=<7.0%), Fasting glucose less than 140mg/dL 3)Patients with written informed concent

Exclusion criteria

Exclusion criteria: 1) Previous use of alpha-glucosidase inhibitor, DPP-4 inhibitor, GLP-1 analog within 3 months 2)Severe ketosis, diabetic coma or diabetic precoma 3)Severe hepatic dysfunction or severe kidney dysfunction 4)Severe infection or serious trauma, perioperative patients or severe injury 5)Hypersensitivity to any ingredient of Voglibose or Acarbose 6)Severe neuropathy 7)Current treatment with steroid 8)Patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
Incretin secretion and postprandial metabolic parameters after loading test meal	—

Secondary

Measure	Time frame
1)Change from baseline in glucose metabolism 2)Change from baseline in lipid metabolism	—

Countries

Japan

Contacts

Public ContactUsuda Rika

Toyama Prefectural Central Hospital Endocrinology and Metabolism

rika.u@po2.nsknet.or.jp(076)424-1531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026